Taurine
What it is
Taurine is a sulphur-containing amino acid found in high concentrations in the heart, brain, skeletal muscle, and retina. Unlike most amino acids, it is not incorporated into proteins but functions as a free amino acid with roles in osmoregulation, calcium handling, antioxidant activity, bile acid conjugation, and modulation of neuronal excitability. It is one of the most abundant amino acids in human tissue, which reflects its broad physiological importance.
Taurine is conditionally essential, the body synthesises it from cysteine and methionine, but endogenous synthesis may be insufficient under certain conditions. This is most clearly established in premature infants, who lack adequate synthetic capacity, and in critical illness or severe physiological stress; the evidence for meaningful insufficiency in otherwise healthy adult populations is less certain. Dietary sources include meat, fish, and seafood; plant-based diets provide very little taurine, and plasma taurine levels are lower in vegetarians and vegans than in omnivores. Premature infants are considered unable to synthesise adequate amounts and taurine is routinely added to infant formulas for this reason.
The compound is perhaps best known to the general public as an ingredient in energy drinks, where it has been present since the early 1990s. This association has generated both popular interest and significant misinformation. Adverse events reported in association with energy drink consumption have been attributed to taurine in some media coverage, but the pharmacologically active ingredient in those contexts is overwhelmingly caffeine, and the evidence does not support attributing harm to taurine specifically at the doses used. Separating the taurine evidence from the energy drink context is necessary for an accurate assessment.
What the evidence shows
The strongest signal in the human trial literature is for cardiovascular outcomes, particularly blood pressure. A meta-analysis by Sun and colleagues (2016) analysing seven randomised controlled trials found a modest but statistically significant reduction in both systolic and diastolic blood pressure with taurine supplementation. The effect sizes were modest, approximately 3mmHg systolic, and the trials were predominantly in populations with pre-existing hypertension or cardiovascular risk factors. Whether these effects translate into meaningful cardiovascular event reduction over the long term has not been demonstrated.
For glucose metabolism, a small number of trials in people with type 2 diabetes or insulin resistance have shown improvements in insulin sensitivity and modest reductions in fasting glucose. The evidence is preliminary and the effect sizes are small.
For exercise performance, the literature is inconsistent and largely uninformative. Some trials report improvements in endurance markers or reduced oxidative stress with supplementation, but effect sizes are small, protocols are heterogeneous, and results do not replicate consistently. No meta-analysis has found a meaningful, reliable performance effect in isolation from other ingredients.
For cognitive function, the human trial evidence is limited. There is substantial preclinical evidence for neuroprotective effects of taurine, and some epidemiological work associating higher taurine levels with healthier cognitive ageing, but translation into well-controlled human intervention trials is at an early stage.
The overall picture is of a compound with genuine physiological importance, a modest cardiovascular signal in at-risk populations, and a broader collection of preliminary or inconsistent findings that do not yet support confident conclusions.
Five questions
Does low status cause harm? The relationship between taurine status and health outcomes is uncertain, and reverse causation is a plausible explanation for much of the available data, lower taurine levels in people with cardiovascular disease or diabetes may reflect the disease state rather than contributing to it. With that caveat, observational data do link lower plasma taurine to higher cardiovascular risk, and conditions including heart failure, diabetes, and ageing are associated with reduced tissue taurine concentrations. Whether low taurine is causally implicated in these outcomes is not established. The conditional essentiality of taurine, the possibility that synthesis becomes insufficient under physiological stress, is biologically credible but not well-characterised at the general population level.
Does supplementation prevent disease? There is no direct evidence from long-term intervention trials that taurine supplementation prevents cardiovascular disease, diabetes, or any other condition. The evidence base is confined to shorter-term trials examining risk markers and physiological parameters rather than clinical endpoints. Prevention claims are not supported by the current literature.
Does it affect biomarkers? Yes, with modest effect sizes in relevant populations. Blood pressure reductions of approximately 3mmHg systolic have been reported in trials in hypertensive individuals. This magnitude is modest at the individual level and its clinical significance is uncertain, a 3mmHg population-level mean reduction does not reliably translate into meaningful benefit for any given individual. Modest improvements in fasting glucose, insulin sensitivity markers, and lipid parameters have been reported in metabolic populations. These are biomarker effects rather than demonstrated clinical outcome benefits, and the clinical significance of the effect sizes observed is uncertain.
Does it help clinical populations? The most credible evidence is in individuals with hypertension, cardiovascular risk factors, heart failure, or metabolic dysfunction. Some trials in heart failure patients have shown improvements in exercise tolerance and cardiac function markers, and the cardiovascular biomarker evidence is more consistent in populations with elevated risk than in healthy individuals. The evidence is Emerging in these populations, suggestive but not yet at the level of a clinical recommendation.
Does it benefit healthy individuals? The evidence for benefit in healthy individuals without cardiovascular or metabolic risk factors is limited. Exercise performance effects have not been consistently demonstrated in healthy trained or untrained individuals. Cognitive effects in healthy younger adults are not established. The case for supplementation in the absence of a relevant clinical context is weak.
Individual variation
Age is a relevant variable. Plasma and tissue taurine concentrations decline with age, and some of the more consistent trial signals are in older adult populations. The neuroprotective hypothesis is most biologically plausible in ageing populations where taurine status may be functionally lower. Older adults with cardiovascular risk factors represent the subgroup where the available evidence is most applicable.
Cardiovascular and metabolic status substantially influences who is likely to respond. The blood pressure and glucose metabolism signals are concentrated in populations with pre-existing risk factors or clinical conditions. In normotensive, metabolically healthy individuals, the evidence does not support a meaningful effect.
Diet affects baseline taurine status. Vegetarians and vegans have lower plasma taurine than omnivores due to absent dietary intake, and may therefore have a wider response window. Whether this translates into greater clinical benefit from supplementation has not been formally studied.
Sex and hormonal status: Oestrogen influences taurine metabolism, with some evidence that oestrogen upregulates cysteine sulphinic acid decarboxylase, an enzyme in the taurine synthesis pathway. Postmenopausal women may have altered taurine metabolism compared to premenopausal women, which is biologically relevant but has not been translated into female-specific supplementation evidence. The existing trial literature does not consistently report sex-stratified analyses.
Renal function: Taurine is handled renally and individuals with impaired kidney function may have altered taurine metabolism. While taurine itself has not been demonstrated to cause renal harm at supplemental doses, caution is reasonable in this population and clinical guidance is appropriate.
Testing and status assessment
Plasma taurine can be measured via amino acid analysis, and reference ranges exist. However, plasma taurine is not a well-validated clinical marker, it reflects recent dietary intake and does not reliably represent tissue concentrations, which are substantially higher and more physiologically relevant in organs such as the heart and brain. Intracellular or tissue taurine measurement is not clinically accessible.
There is no established threshold of plasma taurine below which supplementation is indicated, and no validated protocol for using taurine measurement to guide supplementation decisions. Testing is not routinely recommended as a basis for deciding whether to supplement.
For individuals with conditions associated with reduced taurine status, heart failure, diabetes, renal disease, the clinical management of the underlying condition takes priority, and taurine measurement does not currently alter that management in standard practice.
Safety
Taurine has a well-characterised short-term safety profile. It is well-tolerated at doses up to 3g per day in clinical trials, and some studies have used doses of 6g per day or higher without significant adverse effects. The European Food Safety Authority reviewed taurine safety in 2012 and concluded that supplemental intakes of up to 6g per day do not raise safety concerns in healthy adults.
Long-term safety data beyond 12 months at supplemental doses is limited, and the absence of demonstrated harm over short periods should not be extrapolated to confirmed long-term safety without qualification.
The association of taurine with energy drink-related adverse events warrants explicit clarification. Serious adverse events and deaths associated with energy drink consumption are attributable to caffeine toxicity and, in some cases, alcohol co-ingestion, not to taurine. The doses of taurine in energy drinks (typically 500mg to 2g per can) are within the range used safely in clinical trials. Attributing energy drink harm to taurine is not supported by the evidence.
Taurine has not demonstrated clinically significant interactions with common medications at supplemental doses. Caution is reasonable in individuals with impaired renal function, where altered renal handling of taurine is plausible, and clinical guidance should be sought in this context.
Pregnancy and breastfeeding: taurine is present in breast milk and is considered important for infant development, and it is routinely included in infant formula. Supplementation in pregnancy beyond dietary intake has not been adequately studied and cannot be recommended based on current evidence.
What can reasonably be concluded
Taurine is a physiologically important amino acid with a genuine but modest cardiovascular signal in at-risk populations, a preliminary glucose metabolism signal, and a broader collection of preclinical and mechanistic evidence that has not yet translated consistently into human clinical outcomes. The evidence is most relevant for older adults and individuals with cardiovascular or metabolic risk factors; in healthy younger individuals the case for supplementation is not well supported.
The energy drink association has both inflated consumer interest in taurine and generated unwarranted safety concern. The actual evidence, modest, preliminary, population-specific, sits between these extremes.
Taurine has a reassuring short-term safety profile at supplemental doses. The long-term picture is less well characterised. The cardiovascular biomarker signals are real but modest, and should not be interpreted as equivalent to demonstrated reduction in cardiovascular events.
Where evidence is limited or outcomes are uncertain, conclusions should be treated as provisional and subject to revision as the evidence base develops.